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Pender-Related Differences in Rhythm
ontrol Treatment in Persistent Atrial Fibrillation
ata of the Rate Control Versus Electrical Cardioversion (RACE) Study
ichiel Rienstra, MD,* Dirk J. Van Veldhuisen, MD, FACC,* Vincent E. Hagens, MD,*
delita V. Ranchor, PHD,† Nic J. G. M. Veeger, MSC,§ Harry J. G. M. Crijns, MD,‡
sabelle C. Van Gelder, MD,* for the RACE Investigators
roningen and Maastricht, the Netherlands
OBJECTIVES This study sought to compare whether gender affects the outcome of rate versus rhythm
control treatment in patients with persistent atrial fibrillation (AF).
BACKGROUND Large trials have shown that rate control is an acceptable alternative to rhythm control.
However, the effects of treatment may differ between male and female patients.
METHODS In the Rate Control versus Electrical Cardioversion (RACE) study, 522 patients (192 female)
were included and randomized to rate or rhythm control. The occurrence of cardiovascular
end points and quality of life (QoL) were compared between female and male patients.
RESULTS At baseline, female patients differed from male patients with regard to age, underlying heart
disease, diabetes mellitus, and left ventricular function. Female patients had more AF-related
complaints, and QoL was significantly lower. After a mean follow-up of 2.3  0.6 years,
cardiovascular morbidity and mortality was equally distributed between female (21%) and
male patients (19%). However, in contrast to male patients, female patients randomized to
rhythm control developed more end points (adjusted hazard ratio was 3.1 [95% confidence
interval 1.5 to 6.3], p  0.002), mainly heart failure, thromboembolic complications, and
adverse effects of antiarrhythmic drugs, compared with rate control randomized female
patients. During follow-up, QoL in female patients remained worse compared with that for
male patients. Randomized strategy did not influence QoL in female patients.
CONCLUSIONS In female patients with persistent AF, a rhythm control approach leads to more cardiovascular
morbidity and mortality. Because treatment strategy did not influence QoL in female
patients, a rate control approach may be considered in these patients. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.0782005;46:1298–306) © 2005 by the American College of Cardiology Foundation
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yeveral studies have addressed the issue of gender differ-
nces in the outcome of cardiovascular diseases (1–3). Few
tudies have dealt with gender differences and arrhythmias
4,5). The incidence and prevalence of atrial fibrillation
AF) increases with advancing age and is higher in men than
See page 1307
n women (4). Because there are almost twice as many
omen as men over the age of 75 years, the absolute number
f men and women with AF is equal (5,6). Although AF is
ot fatal, thromboembolic complications, bleeding, and
eart failure are important complications associated with
F. Women in particular (especially those over the age of
5 years) are at increased risk for thromboembolic compli-
ations (7). Bleeding as a complication of oral anticoagula-
ion has also been reported to be more prevalent in women
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Manuscript received February 7, 2005; revised manuscript received April 19, 2005,
ccepted May 15, 2005.8). In addition, gender may affect the selection of antiar-
hythmic drugs for rhythm control of AF because women
re more likely to develop proarrhythmia on QT prolonging
ntiarrhythmic drugs (9). This may reduce the success of
hythm control therapy in female patients (10).
Mortality and morbidity were comparable under long-
erm rate and rhythm control treatment in patients with
ersistent AF (11–14). It remains uncertain, however,
hether this holds both for female patients and for male
atients. The goals of the present substudy of Rate Control
ersus Electrical Cardioversion (RACE) study were: 1) to
nvestigate the long-term outcome, i.e., cardiovascular mor-
idity, mortality, and quality of life (QoL) in female patients
nd male patients; and 2) to evaluate the outcome of rate
nd rhythm control treatment of persistent AF in female
atients and male patients.
ETHODS
tudy design of the RACE study. The study design,
atient characteristics, and results of the RACE study have
een published previously (12). In short, 522 patients (192
emales) with recurrent persistent AF were included and
andomized to rate or rhythm control. Patients were fol-
owed up for at least two years, with a maximum of three
ears. Administration of digitalis, a nondihydropyridine
alcium-channel blocker, and a beta-blocker achieved rate
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October 4, 2005:1298–306 Gender and Treatment of Atrial Fibrillationontrol, alone or in combination. The target was a resting
eart rate of 100 beats/min. Patients assigned to the
hythm control group underwent serial electrocardioversions
nd institution of serial antiarrhythmic drugs, i.e., sotalol,
lass IC antiarrhythmic drugs, and amiodarone. Cardiover-
ion was performed under adequate anticoagulation (target
nternational normalized ratio [INR], 2.5 to 3.5). All
atients received acenocoumarol or fenprocoumon, unless
ong-term sinus rhythm was achieved or when rate control
reated patients were 65 years old and had lone AF. In
hese instances, aspirin (80 to 100 mg daily) was allowed.
nd points. The primary end point was the composite of
eath from cardiovascular cause, heart failure, thromboembolic
omplications, bleeding, severe adverse effects of antiarrhyth-
ic drugs, and the need for a pacemaker implantation. All
vents that occurred between randomization and the end of the
tudy were recorded. Definitions of the composites of the
rimary end point have been described previously (12). A
ommittee of experts, who were unaware of the treatment
ssignments, adjudicated all reported end points.
oL. The QoL was determined using the Dutch version of
he Medical Outcomes Study Short-Form Health Survey
SF-36) questionnaire as has been described before (15). In
hort, the SF-36 contains items for assessing physical health
general health perception, physical functioning, role limi-
ations attributable to physical problems and bodily pain) as
ell as mental health (social functioning, role limitations
ttributable to emotional problems, mental health, and
itality). The QoL was assessed at baseline, after one year,
nd at the end of the study in 126 female patients (66%) and
n 226 male patients (68%). In addition, a healthy age-
atched control group was selected from Dutch subjects,
nd served to validate the Dutch version of the SF-36 (64
ealthy age-matched control female patients and 113
ealthy age-matched control male patients).
tatistical analysis. Baseline descriptive statistics are the
ean  standard deviation or median (range) for continu-
us variables and counts with percentages for categorical
ariables. Differences between groups, in terms of patient
haracteristics and QoL at baseline, different follow-up
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management
CI  confidence interval
HR  hazard ratio
INR  international normalized ratio
NYHA  New York Heart Association
QoL  quality of life
RACE  Rate Control versus Electrical Cardioversion
study
SF-36  Medical Outcomes Study Short-Form
Health Survey
SPAF  Stroke Prevention in Atrial Fibrillationimes, and end of study were evaluated by student t test or tann-Whitney U test, depending on normality of the data,
or continuous data. We determined whether the data were
ormally distributed by using the Shapiro-Wilk test for
ormality. For categorical data, predominantly the Fisher
xact test (in case of binomial proportions) was used; in case
f more than two-response categories, the chi-square test
as used. Kaplan-Meier estimates and Cox proportional
azard regression analyses were performed to study the
nfluence of gender and randomized treatment on the
ccurrence of cardiovascular morbidity and mortality over
ime in the study population. Linearity of the continuous
ariables with respect to the response variable was assessed
y determining the quartiles of their distribution. Thereaf-
er, hazard ratios (HRs) for each quartile were calculated. In
ase of a linear trend in the estimated HRs, the variable was
ntroduced in the model as continuous. If no linearity was
hown, the variable was further categorized by taking
ogether the quartiles with HRs similar in magnitude,
rimarily the median value or otherwise based on clinical
elevance. All patient characteristics, medication use, and
hanges in stroke risk factors during follow-up were in-
luded. All univariate predictors with p 0.1 were tested in
multivariate model, including interaction terms. In the
ultivariate model, a variable was excluded when p  0.05.
n all analyses, a value of p  0.05 was considered
tatistically significant. All analyses were performed accord-
ng to the intention-to-treat principle.
ESULTS
atient characteristics. In the RACE study, 192 female
atients and 330 male patients were included (Table 1). At
aseline, female patients were significantly older than male
atients. Coronary artery disease was less frequently present,
hereas hypertension and diabetes mellitus occurred more
ften in female patients compared with male patients. At
aseline, the systolic blood pressure was higher in female
atients compared with male patients. Atrial sizes were com-
arable, but fractional shortening was higher in female
atients.
There were more female patients with hypertension in
he rhythm control randomized group, in comparison with
emale patients randomized to rate control (72% vs. 53%, p
0.005). No other differences between rate and rhythm
ontrol randomized female patients were observed. The use
f drugs in these two groups at baseline and at the end of the
tudy is shown in Table 2. No important differences
etween female patients and male patients were observed.
ollow-up. Patients were followed up for a mean duration
f 2.3  0.6 years; 49% of the female patients and 51% of
he male patients were randomized to rhythm control. In
he rhythm control strategy, 34 female patients (35%) versus
6 male patients (39%) were in sinus rhythm at the end of
he study (p  NS) after a median of 2 (0 to 11) versus 2 (0
o 6) electrical cardioversions (p  NS), respectively. Con-
inuous oral anticoagulation was used in 74% of the female
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nd in 72% of the male patients (83% rate control, 62%
hythm control, p 0.001). All other patients had their oral
nticoagulation treatment interrupted or stopped. After two
ears of follow-up, the New York Heart Association
NYHA) functional class of heart failure was comparable
etween female patients (75% class I, 25% class II and III)
nd male patients (67% class I, 33% class II and III; p ns).
n both female patients and male patients, a significant
mprovement in NYHA functional class for heart failure
as observed from baseline to end of study (1.5 0.6 vs. 1.3
0.5, p  0.001; and 1.5  0.5 vs. 1.4  0.5, p  0.001,
n female patients and male patients, respectively). There
ere no major differences in heart rate during follow-up
etween female patients and male patients treated with rate
r rhythm control. However, the higher systolic blood
Table 1. Baseline Characteristics of the Patien
Patient Characteristics
Age (yrs)
Total AF duration (days)
Duration present episode of AF (days)
Atrial fibrillation
Atrial flutter
Treatment
Rate control
Rhythm control
Complaints of AF
Palpitations
Dyspnea
Fatigue
NYHA functional class for heart failure*
I
II
III
Coronary artery disease
Old myocardial infarction
Valve disease
Cardiomyopathy
History of hypertension
No heart disease
History of chronic obstructive pulmonary disease
Diabetes mellitus
Previous ischemic thromboembolic complication
Previous bleeding
Heart rate (rest) (beats/min)
Blood pressure (mm Hg)
Systolic
Diastolic
Echocardiographic measurements
Size of left atrium, long-axis (mm)
Size of left atrium, apical view (mm)
Size of right atrium, apical view (mm)
Left ventricular end-diastolic diameter (mm)
Left ventricular end-systolic diameter (mm)
Septal thickness (mm)
Posterior wall thickness (mm)
Fractional shortening (%)
*Chi-square test.
AF  atrial fibrillation; NS  nonsignificant; NYHA ressure in female patients compared with male patients 1emained constantly present during follow-up. During
ollow-up, fractional shortening remained significantly
igher in female patients and improvement was significantly
ore pronounced (Table 3).
ardiovascular morbidity and mortality. The primary
nd point occurred in 41 female patients (21%) and 63 male
atients (19%) (Table 4). The rate of death was similar in
oth groups, 7%. Causes of death were comparable given
he small number. Fatal bleeding occurred only in male
atients. Hospitalization for heart failure and thromboem-
olic complications occurred in similar proportions in fe-
ale patients and male patients. All female patients and
ale patients with a thromboembolic complication had at
east one stroke risk factor. The rhythm at the moment of
he thromboembolic complication was mostly AF (10 fe-
ale patients with AF, 3 female patients in sinus rhythm;
cording to Gender
male Patients
(n  192)
Male Patients
(n  330)
p
Value
71  8 67  9 0.001
4 (27–14,909) 470 (1–14,399) NS
33 (1–399) 32 (1–395) NS
96% 91% 0.03
4% 9%
NS
51% 49%
49% 51%
77% 66% 0.007
33% 24% 0.03
39% 33% NS
47% 35% 0.006
NS
53% 49%
43% 49%
5% 2%
21% 31% 0.01
8% 19% 0.001
21% 14% NS
6% 11% NS
63% 41% 0.001
12% 26% 0.001
12% 16% NS
17% 6% 0.001
16% 13% NS
11% 6% 0.02
91  21 90  21 NS
148  25 141  20 0.001
86  11 85  11 NS
44  6 45  7 NS
63  8 64  9 NS
57  8 58  8 NS
50  6 54  7 0.001
35  7 38  8 0.001
10  2 10  3 NS
9  2 10  2 NS
32  9 29  10 0.03
York Heart Association.ts Ac
Fe
447 male patients with AF and 5 in sinus rhythm), and
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October 4, 2005:1298–306 Gender and Treatment of Atrial Fibrillationredominantly occurred while receiving inadequate antico-
gulant therapy (INR 2). The incidence of bleeding was
ower in female patients compared with male patients.
lmost all bleeding in both the female patients and the male
atients occurred while the INR was 3. Severe adverse
ffects of antiarrhythmics and pacemaker implantations
ccurred mainly in female patients. Adverse effects of
ntiarrhythmic drugs in female patients included sick sinus
Table 2. Treatment at Baseline and End of St
According to Randomized Strategy
Female Pa
Rate Control R
Baseline
Beta-blocker 22
Diltiazem or verapamil 26
Digoxin 66
Class Ic antiarrhythmics 7
Sotalol 26
ACE and AR inhibitors 39
Cholesterol-lowering drugs 12
End of study
Beta-blocker 35
Diltiazem or verapamil 42
Digoxin 67
Class Ic antiarrhythmics 7
Amiodarone 1
Sotalol 12
ACE and AR inhibitors 49
Cholesterol-lowering drugs 12
*p  0.05 female compared with male patients, randomized
ACE  angiotensin-converting enzyme; AR  angioten
Table 3. Echocardiographic Measurements and
Left atrial size, long-axis view (mm)
Female
Male
Left atrial size, apical view (mm)
Female
Male
Right atrial size, apical view (mm)
Female
Male
Left ventricular end-diastolic
diameter (mm)
Female
Male
Left ventricular end-systolic
diameter (mm)
Female
Male
Fractional shortening (%)
Female
Male
Septal wall thickness (mm)
Female
Male
Posterior wall thickness (mm)
Female
Male*p  0.05, female compared with male patients.yndrome (n  7; 4 on flecainide, 1 on sotalol, 2 on
miodarone) necessitating pacemaker implantation in 2,
orsades des pointes (n  1; on sotalol), and rapid, hemo-
ynamically significant atrioventricular conduction during
trial flutter (n  1; on flecainide). In male patients,
orsades des pointes occurred in one while being treated
ith amiodarone and haloperidol, one developed ventricular
achycardia under flecainide, two had digoxin intoxication
n Both Female and Male Patients Stratified
(%) Male Patients (%)
m Control Rate Control Rhythm Control
18 24 17
12 27 21
59 60 52
13 9 12
39 27 37
47 32 36
13 14 14
24 36 25
11 32 17
36 57 34
18 4 18
20 4 19
31 13 24
57 41 43*
17 18 20
thm control.
eptor.
anges Over Time According to Gender
line 1 Year 2 Years
6 45  7 45  6
7 46  7 46  8
8 65  8 66  9
9 65  9 67  10
8 60  8 61  10
8 60  8 62  8
6 51  6 49  6
7* 54  6* 54  7*
7 33  7 32  6
8* 36  8* 38  9*
9 34  8 35  9
10* 33  9 30  11*
2 10  2 10  2
3 11  2 11  3
2 9  2 10  2
2 10  2* 10  2udy i
tients
hythCh
Base
44 
45 
63 
64 
57 
58 
50 
54 
35 
38 
32 
29 
10 
10 
10 
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he other), and one had atrioventricular block under amio-
arone, necessitating pacemaker implantation. Of all sud-
en cardiac deaths in female patients, one patient used
otalol. Pacemaker implantations in female patients were
erformed after atrioventricular node ablation because of
ntolerable symptoms (three patients) and for sick sinus
yndrome unmasked by cardioversion (four patients). In
ale patients, pacemaker implantations were performed
fter atrioventricular ablation because of intolerable symp-
oms in two patients, and for bradycardia during AF in one
atient. The occurrence of bradyarrhythmias during
ollow-up was significantly influenced by female gender
adjusted HR, 4.8 [95% confidence interval (CI) 1.2 to
8.8]; p  0.02), hypertension (adjusted HR, 9.0 [95% CI
.1 to 71.6]; p  0.04), and amiodarone use (adjusted HR,
.8 [95% CI 1.7 to 19.5]; p  0.004).
ender difference in outcome rate versus rhythm con-
rol. Randomized strategy importantly influenced the oc-
urrence of end points in female patients (Table 5, Fig. 1).
he primary end point occurred in 10 female patients (11%)
reated with rate control versus 31 female patients (33%)
reated with rhythm control. Cardiovascular mortality, heart
ailure, thromboembolic complications, serious adverse ef-
ects of antiarrhythmic drugs, and pacemaker implantation
redominantly occurred in female patients treated with
hythm control. In male patients, the occurrence of the
Table 4. Incidence of the Primary End Point a
End Point, % (n)
Female Pa
(n  19
End point 21.4 (41
Death from cardiovascular causes 6.8 (13
Sudden death 4.2 (8)
Heart failure 0.5 (1)
TEC 2.1 (4)
Bleeding —
Heart failure 3.6 (7)
Thromboembolic complications 6.8 (13
Bleeding 1.6 (3)
Severe adverse effects of AAD 4.7 (9)
Pacemaker implantation 3.6 (7)
*Some patients had more than one end point.
AAD  antiarrhythmic drugs; CI  confidence interval;
able 5. Incidence of the Primary End Point and Its Componen
End Point, %
Female Patient
Rate
Control
(n  95)
Rhythm
Control
(n  97)
Ab
nd point 10.5 32.6 21
eath from cardiovascular causes 3.2 10.3 7
eart failure 1.1 6.2 5
hromboembolic complications 2.1 11.3 9
leeding 2.1 1.0 1
evere adverse effects of AAD — 9.3 9
acemaker implantation 2.1 5.2 3Some patients had more than one end point.
AAD  antiarrhythmic drugs; CI  confidence interval.rimary end point was equally distributed between rate and
hythm control treatment.
eterminants of cardiovascular morbidity and mortality.
y Cox regression analysis, all patient characteristics (in-
luding gender); treatment variables (including medication
se and treatment strategy); and changes in blood pressure,
eft-ventricular hypertrophy, atrial sizes, and left ventricular
ysfunction during follow-up were included. In the total
opulation, hypertension, coronary artery disease, heart
ailure NYHA functional class II/III, and previous bleeding
ere independent predictors of the occurrence of the pri-
ary end point, but not gender or age. To investigate the
nfluence of gender on outcome of rate or rhythm control
reatment, we repeated these analyses in female patients and
ale patients, respectively (Table 6). All univariate variables
ith p  0.1, including age, were added stepwise in the
ultivariate models. In male patients, there was no associ-
tion between treatment strategy and adverse outcome.
owever, in female patients there was a significant relation-
hip between rhythm control treatment and event-free
urvival (adjusted HR, 3.1 [95% CI 1.5 to 6.3]; p  0.002)
Fig. 2).
uality of life. Female patients had more AF-related
omplaints, especially palpitations and fatigue (Table 1).
he QoL of female patients was significantly lower than in
ale patients, measured on six of eight scales (Fig. 3A).
ompared with the healthy age-matched female control
ts Components According to Gender*
Male Patients
(n  330)
Absolute Difference
(90% CI)
19.1 (63) 2.3 (4.5 to 9.0)
7.0 (23) 0.2 (4.1 to 3.7)
2.4 (8)
1.2 (4)
0.6 (2)
2.7 (9)
4.2 (14) 0.6 (3.5 to 2.3)
6.7 (22) 0.1 (3.8 to 4.0)
5.5 (18) 3.9 (6.5 to 1.3)
1.5 (5) 3.2 (0.4 to 6.0)
1.2 (4) 2.4 (0.04 to 4.9)
 thromboembolic complications.
cording to Treatment Strategy and Gender*
Male Patients
Difference
% CI)
Rate
Control
(n  161)
Rhythm
Control
(n  169)
Absolute Difference
(90% CI)
32.3 to 10.5) 21.1 17.2 4.0 (4.0 to 11.9)
13.3 to 1.0) 9.3 4.7 4.6 (0.2 to 9.4)
9.6 to 0.6) 5.0 3.6 1.4 (2.3 to 5.2)
15.4 to 3.1) 7.5 5.9 1.5 (3.2 to 6.2)
1.9 to 4.1) 6.2 4.7 1.5 (2.8 to 5.7)
14.4 to 4.2) 1.2 1.8 0.5 (2.8 to 1.7)
7.6 to 1.5) 0.6 1.8 1.2 (3.1 to 0.8)nd I
tients
2)
)
)
)ts Ac
s
solute
(90
.4 (
.2 (
.1 (
.2 (
.1 (
.3 (
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October 4, 2005:1298–306 Gender and Treatment of Atrial Fibrillationroup, QoL in female patients with persistent AF was
ignificantly lower on the general health, physical role
imitations, pain, and vitality SF-36 subscales, thus predom-
nantly on physical health scales (Fig. 3B). Both healthy
omen and women with persistent AF had a worse QoL
han healthy men (data not shown). After 12 months and at
he end of the study, QoL differences between female
atients and male patients remained present. At 12 months,
emale patients scored lower on five of eight SF-36 scales
nd at the end of the study on seven of eight SF-36 scales.
he QoL did not largely change in both groups during
ollow up (data not shown). Additional analysis of QoL in
emale patients was performed to determine the effects of
reatment strategy on QoL. No significant differences be-
ween rate and rhythm control treated patients was found.
ISCUSSION
arge studies have indicated that rate and rhythm control
reatment were comparable with regard to morbidity and
ortality (11–14). The present subanalysis of the RACE
tudy suggests that this may not automatically apply to both
emale patients and male patients. The present data show
hat rhythm control in female patients with recurrent
ersistent AF enhances cardiovascular morbidity and mor-
ality, largely because of more thromboembolic complica-
ions, heart failure, and severe adverse effects of antiarrhyth-
ic drugs.
igure 1. Occurrence of the primary end point according to gender and
andomized strategy. Open bars  rate control; solid bars  rhythm
ontrol.
able 6. Predictors of the Occurrence of the Primary End Point
ver Time of the Female and Male Patients
Baseline Characteristics
Hazard Ratio
(95% CI)
p
Value
emale patients
Rhythm control treatment 3.1 (1.5–6.3) 0.002
ale patients
Rhythm control treatment 0.5 (0.2–1.0) 0.058
Rhythm control  hypertension* 3.2 (1.1–9.5) 0.03
Hypertension 1.0 (0.5–2.1) 0.95
Coronary artery disease 2.1 (1.3–3.6) 0.005
Valve disease 2.1 (1.2–3.8) 0.01o
Significant interaction between rhythm control and hypertension.
CI  confidence interval.ender differences in cardiovascular morbidity and mor-
ality. Although we observed, in line with previous find-
ngs, gender differences in baseline characteristics (8,16,17),
ost remarkably hypertension and diabetes, there were no
ajor differences in the occurrence rate of the primary end
oint between female patients and male patients in the
ACE population. In contrast, in the Framingham Heart
tudy, mortality was higher in female patients compared
ith male patients (18), whereas in the Renfrew/Paisley
tudy, not only mortality but also stroke and heart failure
ook place more frequently in female patients (19). On the
ther hand, the Western Australia Survey found no differ-
nces in the cardiovascular and all-cause mortality rates
etween female patients and male patients (20). In all of
hese studies, no data on actual treatment strategy were
rovided.
We noticed, however, important differences in the distri-
ution of the components of the primary end point between
emale patients and male patients. First, in contrast to
revious data, bleeding occurred predominantly in male
atients (8,21). Our total annual bleeding rate was 1.7%
male patients, 2.3%; female patients, 0.7%), which com-
ares favorably with the annual bleeding rate during oral
nticoagulation therapy in the Stroke Prevention in Atrial
ibrillation (SPAF)-I, -II, and -III studies (1.5%, 1.7%, and
.1%, respectively) (22–24). As mentioned before, bleeding
ccurred predominantly at the moment of a too high INR.
herefore, the lower bleeding rate in female patients may
ave been related to the fact that female patients may have
een less likely to receive adequate anticoagulant therapy, as
as been described before (8,25), or did not take their
nticoagulant therapy.
Secondly, severe adverse effects of antiarrhythmic drugs
igure 2. Event-free survival of female patients stratified to rate or rhythm
ontrol treatment.ccurred most frequently in female patients. Although
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lass IA or III antiarrhythmic drugs (9), this gender differ-
nce was previously not observed (26). Also the Atrial
ibrillation Follow-up Investigation of Rhythm Manage-
ent (AFFIRM) investigators did not describe any differ-
nce in prevalence of torsades des pointes between female
atients and male patients (27). In our study, most adverse
ffects of antiarrhythmic drugs, however, were not related to
he occurrence of tachycardias, but instead to bradyarrhyth-
ias, i.e., unmasking of the sick sinus syndrome and
ymptomatic bradycardia. This could be a chance finding
ecause the numbers are small. It also may have been caused
y the use of negative chronotropic drugs, but this was not
ignificantly different between rhythm control treated fe-
ale patients and male patients.
Thirdly, in accordance with the previous text, more
acemaker implantations were observed in female patients,
hich was largely because more female patients had sick
inus syndrome.
emale gender and outcome of rate and rhythm control
reatment. One of the major findings of the present anal-
sis was an important difference in event-free survival
etween rhythm control randomized and rate control ran-
omized female patients. The latter difference was not
igure 3. Quality of life scores of female patients versus male patients (A)
.05. Solid bars  female patients (n  128); shaded bars  male patiebserved in male patients. Female patients randomized to mhythm control had a three times greater risk of developing
ardiovascular morbidity and mortality, which was mainly
ecause of the higher occurrence rate of heart failure,
hromboembolic complications, and severe adverse effects of
ntiarrhythmic drugs.
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ur annual thromboembolic complication rate was slightly
igher than observed in the SPAF studies (2.9% vs. 2.3%,
.3%, and 1.9% in the SPAF-I, -II, and -III studies,
espectively). Whereas the yearly rate was comparable in the
ate and rhythm control randomized male patients (3.2% vs.
.5%), thromboembolic complications almost only occurred
n female patients randomized to rhythm control (0.9% vs.
.9%, respectively). Although after correcting for the ob-
erved differences in hypertension history and blood pres-
ure, rhythm control remained associated with a worse
rognosis in female patients and not in male patients, we
annot definitely exclude that hypertension has influenced
utcome in the female rhythm control strategy.
ender differences in QoL. The QoL in female patients
as impaired in comparison with that of healthy female
ontrols. In agreement with this finding, female patients
xperienced more complaints of AF, especially palpitations
nd fatigue. This is in accordance with previous reports
howing that patients with heart disease have lower QoL
cores than healthy controls (13,28). In comparison with
ale patients, female patients had lower QoL scores on
lmost all SF-36 subscales. It is difficult to explain these
ender differences. However, in the Canadian Trial of
trial Fibrillation, QoL was also impaired in female pa-
ients compared with male patients, despite comparable
everity of underlying heart disease (29). This reduced QoL
n female patients may have been caused by the presence of
ore complaints, which are known to be important deter-
inants of reduced physical and mental health scores (15).
his can be partly attributable to a heightened sensitivity to
he disease and symptoms, a difference in perception of
llness, or a lower threshold of women for experiencing
llness burden (29), but also to a lower chest volume or less
hest thickness. Another possibility can be that more
omen are more likely to seek medical care when they
xperience symptoms (30). In addition, it may be possible
hat female patients are more prone to depression and
nxiety than male patients (31,32), which may be reflected
y the more impaired mental health in female patients
ompared with male patients in our study.
tudy limitations. The present study is a post-hoc analysis,
nd therefore is not designed to determine gender differ-
nces in outcome after treatment. Another important lim-
tation is the relatively small number of female patients and
he disproportionate number of female patients with hyper-
ension assigned to the rhythm control strategy. However,
fter correcting for these differences in hypertension history,
lood pressure at baseline, and the change of the blood
ressure during follow-up, rhythm control remained asso-
iated with a worse prognosis in female patients.
ONCLUSIONS
n female patients with recurrent persistent AF, a rhythm
ontrol treatment enhances cardiovascular morbidity and
1ortality, largely because of the occurrence of heart failure,
hromboembolic complications, and severe adverse effects of
ntiarrhythmic drugs. Because treatment strategy does not
ave any influence on QoL in female patients, a rate control
pproach may be preferable.
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